Hims & Hers Health, Inc. (NYSE:HIMS) Insider Soleil Boughton Sells 4,152 Shares

Hims & Hers Health, Inc. (NYSE:HIMS) insider Soleil Boughton sold 4,152 shares of Hims & Hers Health stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $60.69, for a total value of $251,984.88. Following the sale, the insider now directly owns 157,345 shares of the company’s stock, valued at $9,549,268.05. This trade represents a 2.57 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Soleil Boughton also recently made the following trade(s):

• On Monday, February 3rd, Soleil Boughton sold 4,153 shares of Hims & Hers Health stock. The stock was sold at an average price of $35.30, for a total value of $146,600.90.
• On Tuesday, January 21st, Soleil Boughton sold 54,153 shares of Hims & Hers Health stock. The stock was sold at an average price of $29.90, for a total value of $1,619,174.70.
• On Monday, January 6th, Soleil Boughton sold 268,932 shares of Hims & Hers Health stock. The stock was sold at an average price of $27.75, for a total value of $7,462,863.00.
• On Tuesday, November 26th, Soleil Boughton sold 2,343 shares of Hims & Hers Health stock. The stock was sold at an average price of $29.90, for a total value of $70,055.70.

Hims & Hers Health Stock Performance

Shares of HIMS opened at $66.28 on Friday. Hims & Hers Health, Inc. has a one year low of $9.22 and a one year high of $72.98. The stock has a market capitalization of $14.48 billion, a price-to-earnings ratio of 150.64 and a beta of 1.35. The stock has a 50 day moving average price of $34.66 and a 200 day moving average price of $25.48.

Analyst Upgrades and Downgrades

A number of research firms recently commented on HIMS. Bank of America lifted their target price on Hims & Hers Health from $18.00 to $21.00 and gave the stock an “underperform” rating in a report on Thursday. TD Cowen reissued a “buy” rating and issued a $28.00 price target on shares of Hims & Hers Health in a report on Wednesday, November 20th. Canaccord Genuity Group boosted their price target on Hims & Hers Health from $38.00 to $68.00 and gave the company a “buy” rating in a report on Wednesday. Needham & Company LLC boosted their price target on Hims & Hers Health from $28.00 to $31.00 and gave the company a “buy” rating in a report on Monday, January 6th. Finally, Citigroup downgraded Hims & Hers Health from a “neutral” rating to a “sell” rating and boosted their price target for the company from $24.00 to $25.00 in a report on Friday, January 10th. Two research analysts have rated the stock with a sell rating, eight have assigned a hold rating and seven have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $28.53.

Hedge Funds Weigh In On Hims & Hers Health

A number of institutional investors and hedge funds have recently added to or reduced their stakes in HIMS. Farallon Capital Management LLC boosted its stake in Hims & Hers Health by 64,338.5% during the fourth quarter. Farallon Capital Management LLC now owns 8,377,000 shares of the company’s stock worth $202,556,000 after buying an additional 8,364,000 shares during the last quarter. Arrowstreet Capital Limited Partnership boosted its stake in Hims & Hers Health by 192.0% during the fourth quarter. Arrowstreet Capital Limited Partnership now owns 6,304,202 shares of the company’s stock worth $152,436,000 after buying an additional 4,145,305 shares during the last quarter. Vanguard Group Inc. boosted its stake in Hims & Hers Health by 11.1% during the fourth quarter. Vanguard Group Inc. now owns 20,257,116 shares of the company’s stock worth $489,817,000 after buying an additional 2,020,722 shares during the last quarter. Yong Rong HK Asset Management Ltd acquired a new position in Hims & Hers Health during the fourth quarter worth $41,104,000. Finally, Renaissance Technologies LLC boosted its stake in Hims & Hers Health by 29.0% during the fourth quarter. Renaissance Technologies LLC now owns 6,951,152 shares of the company’s stock worth $168,079,000 after buying an additional 1,562,302 shares during the last quarter. Institutional investors and hedge funds own 63.52% of the company’s stock.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.